Anti-DOCK4 monoclonal antibody
Anti-DOCK4 antibody for FACS & in-vivo assay
Go to DOCK4/DOCK4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-MP2087-Ab-1/ GM-Tg-hg-MP2087-Ab-2 | Anti-Human DOCK4 monoclonal antibody | Human |
GM-Tg-rg-MP2087-Ab-1/ GM-Tg-rg-MP2087-Ab-2 | Anti-Rat DOCK4 monoclonal antibody | Rat |
GM-Tg-mg-MP2087-Ab-1/ GM-Tg-mg-MP2087-Ab-2 | Anti-Mouse DOCK4 monoclonal antibody | Mouse |
GM-Tg-cynog-MP2087-Ab-1/ GM-Tg-cynog-MP2087-Ab-2 | Anti-Cynomolgus/ Rhesus macaque DOCK4 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-MP2087-Ab-1/ GM-Tg-felg-MP2087-Ab-2 | Anti-Feline DOCK4 monoclonal antibody | Feline |
GM-Tg-cang-MP2087-Ab-1/ GM-Tg-cang-MP2087-Ab-2 | Anti-Canine DOCK4 monoclonal antibody | Canine |
GM-Tg-bovg-MP2087-Ab-1/ GM-Tg-bovg-MP2087-Ab-2 | Anti-Bovine DOCK4 monoclonal antibody | Bovine |
GM-Tg-equg-MP2087-Ab-1/ GM-Tg-equg-MP2087-Ab-2 | Anti-Equine DOCK4 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-MP2087-Ab-1/ GM-Tg-hg-MP2087-Ab-2; GM-Tg-rg-MP2087-Ab-1/ GM-Tg-rg-MP2087-Ab-2; GM-Tg-mg-MP2087-Ab-1/ GM-Tg-mg-MP2087-Ab-2; GM-Tg-cynog-MP2087-Ab-1/ GM-Tg-cynog-MP2087-Ab-2; GM-Tg-felg-MP2087-Ab-1/ GM-Tg-felg-MP2087-Ab-2; GM-Tg-cang-MP2087-Ab-1/ GM-Tg-cang-MP2087-Ab-2; GM-Tg-bovg-MP2087-Ab-1/ GM-Tg-bovg-MP2087-Ab-2; GM-Tg-equg-MP2087-Ab-1/ GM-Tg-equg-MP2087-Ab-2 |
Products Name | Anti-DOCK4 monoclonal antibody |
Format | mab |
Target Name | DOCK4 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-DOCK4 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species DOCK4 VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-MP2087 |
Target Name | DOCK4 |
Gene ID | 9732,238130,366608,703726,482407,101082809,534227,100055674 |
Gene Symbol and Synonyms | 5330406C03,6330411N01Rik,C030023J22,DOCK4,mKIAA0716 |
Uniprot Accession | Q8N1I0 |
Uniprot Entry Name | DOCK4_HUMAN |
Protein Sub-location | Transmembrane Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000128512 |
Target Classification | N/A |
The target: DOCK4, gene name: DOCK4, also named as . This gene is a member of the dedicator of cytokinesis (DOCK) family and encodes a protein with a DHR-1 (CZH-1) domain, a DHR-2 (CZH-2) domain and an SH3 domain. This membrane-associated, cytoplasmic protein functions as a guanine nucleotide exchange factor and is involved in regulation of adherens junctions between cells. Mutations in this gene have been associated with ovarian, prostate, glioma, and colorectal cancers. Alternatively spliced variants which encode different protein isoforms have been described, but only one has been fully characterized. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.